BC
RXRX icon

Bridgefront Capital’s Recursion Pharmaceuticals RXRX Stock Holding History

Bridgefront Capital’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-17,551
Closed -$175K – 637
2024
Q1 		$175K Buy
+17,551
New +$195K 0.13% 327
2023
Q4 		– Sell
-14,490
Closed -$111K – 542
2023
Q3 		$111K Buy
+14,490
New +$145K 0.08% 354
2023
Q2 		– Sell
-14,610
Closed -$97.4K – 644
2023
Q1 		$97.4K Buy
+14,610
New +$116K 0.06% 391

Other funds holding RXRX

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bridgefront Capital's RXRX Position: Q2 2024 in Review

Bridgefront Capital sold out of Recursion Pharmaceuticals (RXRX) in Q2 2024, closing a stake of 17,551 shares — an estimated $175K sold.

Bridgefront Capital first reported a position in RXRX in Q1 2023 and held it in 3 quarters. The position peaked at $175K in Q1 2024. 270 funds tracked by Wall St. Rank hold RXRX as of Q2 2024.

  • Bridgefront Capital reported no remaining Recursion Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Bridgefront Capital sold 17,551 Recursion Pharmaceuticals shares in Q2 2024, an estimated $175K.
  • Bridgefront Capital first reported a position in Recursion Pharmaceuticals in Q1 2023 and held it in 3 quarters.
  • Bridgefront Capital's Recursion Pharmaceuticals position peaked at $175K in Q1 2024.
  • 270 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2024.

Based on Bridgefront Capital's 13F filing for Q2 2024, filed 14 Aug 2024.